Boston Neurosciences (BNS) is a clinical-stage, venture-backed company headquartered in Boston with ISO 13485-certified operations in Lithuania, focused on the development of a non-invasive intracranial pressure monitoring platform for the diagnosis of altered intracranial pressure dynamics for neurological and ophthalmological applications. Its first product is a self-calibrating instrument that uses image-guided transcranial Doppler ultrasound technology to measure intracranial pressure.
The underlying technology was developed at the Telematics Institute of the Kaunas Technological University. The Company was founded in 2013.
An independent medical technology company specialising in diabetes, Cellnovo has developed and markets the first mobile, connected, all-in-one diabetes management system that helps make life easier for patients. Compact, intuitive and entirely connected, Cellnovo’s insulin pump comprises a mobile touchscreen controller with an integrated blood glucose meter. This unique device allows optimal management of insulin delivery whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient’s condition to be continually monitored by family members and healthcare professionals in real time*.
Cellnovo is currently participating in several major Artificial Pancreas projects with Diabeloop, TypeZero and Horizon 2020 to develop automated insulin delivery systems.
Click Therapeutics, Inc. develops and commercializes software as prescription medical treatments for people with unmet medical needs. Through cognitive and neurobehavioral mechanisms, Click’s Digital Therapeutics™ enable change within individuals, and are designed to be used independently or in conjunction with biomedical treatments. The Clickometrics® adaptive data science platform continuously personalizes user experience to optimize engagement and outcomes. Following a groundbreaking clinical trial, Click’s industry-leading smoking cessation program is available nationwide through a wide variety of payers, providers, and employers. Click’s lead prescription program is entering into a multi-center, randomized, controlled, parallel-group, phase III FDA registration trial for the treatment of Major Depressive Disorder in adults.
CorFlow Therapeutics is incorporated in Baar, Switzerland, and closed it’s Seed financing round in September 2016 and completed the first closing of the Seed+ round in October 2017. Both rounds were lead by leading cardiovascular seed investors who over decades have successfully invested in innovative medical device companies such as CoreValve and CardiAQ. The rounds were also sup ported by interventional cardiology key opinion leaders such as Jacques Séguin, Jean-Claude Laborde and Arshad Quadri (“Q”). Finally, the seed rounds were funded by leading cardiovascular device distributors in Europe, Japan, Latin America and China.
The company plans successive investment rounds and invites investors who want to support an innovative technology to diagnose and treat microvascular obstruction to participate in these upcoming rounds.
CorTec is a young medical engineering company focused on enabling the communication between the nervous system and technology. As innovation leader in the field of neurotechnology we support with our solutions the development of new therapies which are based on the patients’ needs. The special strength of our developmental work lies in its holistic approach. Our technology is built upon one single thought – from the basic idea up to its subsequent therapeutic use. This way, we realize technological innovations for the development of new therapies, rehabilitative and assistive technologies that cannot be achieved using conventional methods. CorTec is a limited liability company that was founded in Freiburg in September 2010. The company is currently located at the University of Freiburg’s Airport Campus. In summer of 2018 CorTec will move into new premises closeby including own clean room facilities. Thus, a continued growth of the company is ensured as well as the existing interconnection with science and research.
CybeReha SA, a Swiss medical device company founded in 2017 by a leadership team combining extensive experience (40+ years) in neuromuscular electrostimulation and success track record (40+ years) in developing and launching complex medical devices both in major medtech companies and start-ups. CybeReha SA is developing, manufacturing and marketing a robotic assisted muscles electrostimulation breakthrough innovation to improve hemiplegic/paraplegic patients rehabilitation outcomes following stroke or spinal cord injury (SCI) respectively.
Awarded for “most innovative German startup” from German business magazine Bilanz, DiaMonTech has developed a medical device that non-invasively measures your blood glucose without finger pricking, a drop of blood, or a test strip. Simply relax your fingertip on the sensor, wait 5 to 15 seconds, and your blood glucose level will be displayed. Our patented technology works with an invisible infrared light beam that looks into your skin and counts glucose molecules.
Diabetes is a global challenge. More than 400 million people worldwide suffer from the disease. Our goal is to make checking your blood glucose level as easy as unlocking your phone. You will be able to get measurements throughout the day without pain or extra costs. Diabetologists suggest that more frequent blood glucose measurements can lead to better overall diabetes management and less diabetes-related illnesses. Until there’s a cure for diabetes, DiaMonTech can make living with it much easier.
InfiniteVision Optics™ is a privately-held company headquartered in Strasbourg, France. Our mission is to provide the best possible vision to patients after cataract surgery. Cataract treatment is the most frequent surgical intervention in the world with approximately 80’000 operations per day. With the surgery it is possible to correct the patient far- or nearsightedness providing sharp vision at one or several distances. Our Precisight® lens, developed by US ophthalmic surgeon Dr. Theodore P. Werblin, allows for easy adjustment of the visual outcome for such patients. With the Precisight® lens surgeons know that they don’t need to leave cataract patients with a sub-optimal outcome.
InfiniteVision Optics’ Precisight® IOL system is commercially available in Europe. The company is ISO 13485:2016 certified.
Implandata Ophthalmic Products GmbH is a medical device company, based in Hannover Germany. With our transformative products we are addressing a vastly underserved area in care of glaucoma patients, by combining innovative medical technology with state of the art information technology. By this we are creating disruptive solutions for better and more efficient glaucoma therapy, to the benefit of glaucoma patients, their families and care givers.
Our first product EYEMATE for use at primary open angle glaucoma patients is now CE certified and will be launched in Europe shortly. Further product versions are in development and clinical investigation, introduced to broad clinical use in near future.
Our activities are executed by experienced and highly motivated staff and supported by seasoned investors and world class clinical and scientific advisors. We collaborate with prestigious institutes in order to present the most advanced and utile products to patients and the medical community. And we all have the goal to contribute with our products to better glaucoma care and by this sustain quality of life for patients and their families.
Kejako develop non-invasive solution for demanding presbyopic patients seeking to keep their quality of life through the compensation of visual accommodation decay. Our promise, unlike any other existing surgical solution, is to delay the need for reading glasses without compromising the patient’s quality of vision.
Kejako built first and proprietary full eye 3D parametric model combined with multi-physics numerical modeling to compute the full eye’s normal optical and mechanical behavior, as well as resulting impacts due to a specific eye disease. Eventually it will be used to optimize each patient’s treatment, enabling to plan and control the corresponding customized procedure.
Through the power of this model, Kejako is addressing presbyopia in the field of ophthalmology, with an anti-aging mindset in order to treat the gradual loss of visual accommodation.
Presbyopia appears with age as soon as individuals start struggling with their near sight. One basic solution against presbyopia symptoms are reading glasses.
However, Demanding midlifers are often not ready to wear this aging symbol, sometimes their first pair of glasses, and always a true impairment. Other external optical solutions, such as contact lenses and progressive spectacles, are coming with drawbacks too.
These targeted midlifers are fully aware of anti-aging procedures to look as young as they feel. Therefore, they are looking for alternatives to reading glasses, and mostly heavy invasive surgeries are available. On top of the invasiveness, current surgeries are coming with visual compromises.
Therefore, Kejako focus on personalized anti-aging laser treatments to maintain enough capacity of visual accommodation.
Actually, our customized treatments are to treat the root cause of presbyopia through serial non-invasive procedures from early presbyopia and until cataract develops to keep actual accommodation amplitude always above spectacles dependency.
This recurrent treatment will bring preservation of patient’s quality of life, comfort of vision and aesthetic outcome. Kejako has the potential to become the next generation standard of care in personalized ophthalmic anti-aging medicine.
Lophius Biosciences GmbH
Lophius Biosciences is a privately-held German biotechnology company focusing on the development and marketing of innovative immune diagnostic systems to improve therapy control and personalized treatment of patients in the area of transplantation, infectious and autoimmune diseases.
The company’s developments are based on its expertise in cell-mediated immunity as well as on its proprietary T-activation® and Reverse T Cell Technology platforms. Whereas the T-activation® technology platform allows an efficient stimulation of a broad spectrum of clinically-relevant immune effector cells to accurately measure the cell-mediated immunity, the Reverse T Cell Technology platform can distinguish between active and memory T cells to develop innovative diagnostics.
With its T-Track® CMV leading product, based on T-activation® technology, Lophius offers a highly sensitive, reliable and standardized CE-marked in vitro diagnostic solution to measure the functionality of CMV-specific cell-mediated immunity. T-Track® CMV assists clinicians in the risk stratification of CMV disease in immunocompromised patients, toward an improved and individualized patient management.
Lunaphore was born out of 9 years of R&D at the Swiss Federal Institute of Technology and is currently developing laboratory automation solutions* with potential for research and tissue diagnostics based on a unique microfluidic technology, called Fast Fluidic Exchange (FFeX).
Lunaphore’s overall goal is to decrease the time while maintaining the quality of the stainings.
Novian Health is a privately held medical device company based in Chicago with a subsidiary in Evry, France. It has developed the Novilase® Laser System, image-guided treatment that enables physicians to ablate tumors. Novilase Breast Therapy uses parametrically controlled heating to ablate breast tumors with improved outcomes and lower costs versus surgery.
Novian was founded by Dr. Kambiz Dowlat, a former professor of surgery at Rush University Medical Center in Chicago and a leading specialist in breast cancer diagnosis and treatment. Early on he recognized that imaging would be able to detect earlier stage tumors and that a minimally invasive alternative to surgery would be beneficial for patients.
Novian Health received U.S. FDA 510(k) clearance for the treatment of benign breast tumors (i.e., fibroadenomas) and ablation of soft tissue.
Recently, a clinical trial evaluating Novilase Breast Therapy for the focal destruction of malignant breast tumors completed enrollment in the U.S. and UK, and a parallel trial remains ongoing in France. A CE Mark is being sought based on these results.
FDA approval for the treatment of malignant breast tumors will be pursued following completion of a confirmatory clinical trial. Other tumor sites and indications are also being explored.
Novilase is a procedure that can be performed in an outpatient setting with only local anesthesia, offering potentially significant advantages over surgery including minimal scarring, quicker recovery times, and less pain or fatigue. Novilase may be performed by physicians (e.g., surgeons and radiologists) with experience in image-guided procedures (e.g., breast biopsies).
Vivior provides a service for all customers and patients that require a solution to improve their vision. Our objective behavioral data supports experts like ophthalmic surgeons, optometrists, opticians and others to offer personalized solutions to their customers and patients. The specific solution - be it an intraocular lens for cataract patients, laser eye surgery or progressive spectacle lenses - will be customized to the customer’s and patient’s lifestyle and visual needs.
Our Visual Behavior Monitor consists of sensors measuring distance, ambient light and color, an accelerometer, a gyroscope and a magnetometer with a low-energy Bluetooth interface. It is worn on prescription or clear glasses and the data is uploaded to the cloud for processing and analysis.